PER® Miami Breast Cancer Conference | Conference

Dr. Gradishar on Using Genetic Testing to Identify Actionable Results in Breast Cancer

March 9th 2018

William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the utilization of genetic testing in breast cancer to identify actionable results for patients.

Ribociclib Active Across Premenopausal Breast Cancer Subgroups

March 9th 2018

The progression-free survival benefit for ribociclib in pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer was sustained across patient subgroups, according to findings from the phase III MONALEESA-7 trial.

Olaparib Breast Cancer Efficacy Highlighted in Added Analyses

March 8th 2018

Improvements in progression-free survival with olaparib (Lynparza) remained consistent regardless of baseline tumor burden for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.

Dr. Tripathy on Impact of Olaparib Approval in BRCA-Positive Breast Cancer

March 8th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of olaparib (Lynparza) for patients with BRCA-positive breast cancers and the impact it has had on clinical practice. Tripathy shared this insight in an interview during the 35th Annual Miami Breast Cancer Conference.

Expert Discusses State of Bone-Targeted Therapy in Breast Cancer

March 27th 2017

Adam M. Brufsky, MD, PhD, discusses considerations for using denosumab and zoledronic acid in patients with breast cancer.

Novel Approaches in Male Breast Cancer

March 24th 2017

Male breast cancer is a rare and poorly understood disease, but recent molecular studies have revealed fundamental differences from female breast cancer that could help guide treatment strategies toward a more tailored approach.

AR Emerges as a Potential Target in Triple-Negative Breast Cancer

March 24th 2017

Whereas the androgen receptor (AR) is a common target in prostate cancer, emerging findings are showing a potential role for targeting AR in breast cancer, as well.

Sexual Health Counseling Should Be Paired With AI Breast Cancer Treatment

March 15th 2017

Preventive sexual counseling can be effective in reducing sexual dysfunction resulting from the treatment of breast cancer patients with aromatase inhibitors; however, that intervention should be provided early in treatment and supported by encouragement from providers.

Neoadjuvant Therapy Improves Breast Conservation Outlook

March 15th 2017

Debu Tripathy, MD, provided an update on neoadjuvant strategies in HER2-positive breast cancer at the 2017 Miami Breast Cancer Conference.

HER2 Gene Testing Guidelines May Misclassify Patients

March 13th 2017

Michael F. Press, MD, PhD, discusses issues with the ASCO-CAP guidelines on assessment of HER2 amplification by fluorescence in situ hybridization testing.

New Treatments Offer Hope for Patients With TNBC

March 13th 2017

Hope Rugo, MD, highlights the latest efforts to improve outcomes in triple-negative breast cancer.

Sandra Lee States Her Reasons for Bilateral Mastectomy

March 12th 2017

For television personality, author, and lifestyle maven Sandra Lee the roots of her controversial decision to have a bilateral mastectomy go back to her childhood, when her grandmother was diagnosed with an advanced and aggressive form of stomach cancer.

Has PARP Inhibition Finally Arrived in Breast Cancer?

March 12th 2017

The success of olaparib in a phase III trial and recent data for other emerging agents has reversed the PARP narrative in breast cancer, Kimberly Blackwell, MD, said in a presentation at the 34th Annual Miami Breast Cancer Conference.

Immunotherapy Combos on Horizon for Breast Cancer

March 12th 2017

Multiple ongoing clinical trials are evaluating various immunotherapy strategies for patients with breast cancer, with combinations representing the most potential for future success.

Dr. Brufsky on Choosing When to do a Multiparameter Genomic Assay

March 12th 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses when to do a multiparameter genomic assay for a patient with early-stage breast cancer.

Dr. O'Shaughnessy on Differentiating Between CDK 4/6 Inhibitors

March 11th 2017

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses differentiating between CDK 4/6 inhibitors in breast cancer.

Study Shows Healthcare Utilization and Costs for mTNBC

March 11th 2017

Healthcare resource use and costs remain high among patients with metastatic triple-negative breast cancer, indicating a need for better targeted treatments for this patient class.

Dr. Hurvitz on Eliminating Anthracyclines in HER2+ Breast Cancer Treatment

March 11th 2017

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses data supporting the elimination of anthracyclines in HER2-positive breast cancer treatment.

Novel Agents Improve Outcomes in HR+ Breast Cancer

March 11th 2017

Adding CDK4/6 and mTOR inhibitors to standard endocrine therapy has significantly improved outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer, William J, Gradishar, MD, explained in a presentation at the 34th Annual Miami Breast Cancer Conference.

Butterfly Effect May Foil Genomic Medicine

March 11th 2017

The so-called butterfly effect, in which a small creature can cause something on the scale of an earthquake merely by flapping its wings, is fodder for debate on whether the digital revolution in medicine can deliver on its promise for precision medicine.